INFLUENCE OF GENETIC ENGINEERED BIOLOGICAL THERAPY ON THE COURSE OF SEVERE BRONCHIAL ASTHMA ON THE EXAMPLE OF A CLINICAL CASE

Borisova Ekaterina Petrovna, Gorshenina Margarita Semenovna

This clinical case demonstrates the effect of genetically engineered biological therapy on the course of severe bronchial asthma. Before initiation of genetically engineered biological therapy, the patient had an uncontrolled course of the disease according to the ACQ-5 questionnaire of 3.4 points, the need for high doses of inhaled glucocorticosteroids in combination with long-acting bronchodilators. After treatment with tezepelumab, after 3 months, an improvement in well-being was noted in the form of decreased dyspnea, no suffocation, a decrease in the frequency of exacerbations, according to the ACQ-5 questionnaire - 1.4 points, which means partial control of bronchial asthma. In basic therapy, the dosage of inhaled glucocorticosteroids was reduced to average values. Based on the example of this clinical case, it can be concluded that the use of genetically engineered biological therapy allows controlling the symptoms of severe bronchial asthma, reducing the risk of severe exacerbations and hospitalizations, and preventing side effects from high doses of inhaled glucocorticosteroids and the use of short-acting bronchodilators.

Keywords:severe bronchial asthma, genetically engineered biological therapy.